

Agricultural PPPs – a horizon scan

Mike Robinson

PPP workshop Zürich May 30th 2011

The time perspective

Megatrends

- The current megatrends of Demographics and Climate Change, have put agriculture and food security at the forefront of global debate.
- At the same time, the trend of Souvereign Debt has resulted in stagnating public funding (in real terms) for R&D, and increased the need for global public organizations like CGIAR* to seek new strategic partnerships.
- Despite the obvious potential importance of Public-Private Partnerships (PPP) in agriculture, to date "few success stories that are pro-poor have emerged, and even fewer examples have surfaced where partnerships have contributed to food security, poverty reduction and economic growth" (IAASTD Global Report, 2009)
- This review poses the question what can be done to improve success of PPPs in agriculture and mitigate against the risks of an increasingly uncertain and complex (VUCA) environment

^{*} On average, <u>each</u> of the top 10 CP companies spent almost as much (\$509 mio) as the whole of CGIAR (15 centers, \$579 mio) on R&D in 2009. (source CGIAR Annual Report, 2009)

The landscape of AG PPPs: the dataset

(37 projects, mainly in 2000-2010)

Table 3. Public–private partnerships with the "Big 10s" in the crop-science and agri-food sector. 2004

Sector/firm/country of headquarters ^a	Sales (million U.S. dollars)	Number of partnerships with CGIAR center ^b	Center
Crop-science sector			
Syngenta, Switzerland	7,270	7	CIMMYT, ICRISAT, Bioversity Int'l, and IRRI
Pioneer Hi-Bred International, United States	4,830	5	CIMMYT, ICRISAT, and Bioversity Int'l
Bayer Crop-Science, Germany	7,390	4	ICARDA, IFPRI, IRRI, and ICRISAT
Monsanto, United States	5,220	2	IRRI
BASF, Germany	4,170	2	CIMMYT
Grupo Limagrain, France	965	1	CIMMYT
Dow AgroSciences, United States	3,370	0	
Savia, Mexico	611	0	
Advanta, the Netherlands	398	0	
Agrifood sector			
Unilever, United Kingdom/Netherlands	25,670	3	World Agroforestry Centre, IWMI
Mars, United States	17,000	1	IITA
Coca Cola, United States	19,564	1	ICRISAT
Nestlé, Switzerland	54,254	0	

Spielmann, Hartwich & Grebmer, 2007

Insight:

- Only a limited number of records of large AG PPPs are available in the public domain (Spielmann et al. 2004, 2007)
- OThere is no consistent database on AG PPPs, comparable to that in the Health R&D area (e.g. database of the Initiative for Public Private Partnerships for Health, IPPPH has 90 records): and therefore little opportunity for cross project knowledge sharing

This review is based on a dataset extracted from the IFPRI database and an independent deep web search.


syngenta foundation

for sustainable

agriculture


The landscape of AG PPPs: the linkages

(37 projects, mainly in 2000-2010)



UCINET software (Bugatti et al., 2002).

37 projects since ~2000




Size of nodes: no. of PPP projects

Lines: represent links connecting public institutions which share the same private partners

The landscape of AG PPPs: the stakeholders

(Agricultural PPPs mainly in 2000-2010)



for sustainable

agriculture

The role of enabling hubs (example project: African Biofortified Sorghum)

AATF (African Agricultural Technology Foundation). Activities incl. Banana X. Wilt, Water Efficient Maize for Africa, Africa Biofortified Sorghum. (ABS) **Partnership facilitator** between public and private sectors on transfer and use of appropriate agricultural technologies.

•intellectual property & proprietary information

- aspects of regulatory compliance
- technology inventories
- •freedom to operate (FTO) assessments,
- •policy manual and provided licensing advisory services.

Insight: do we need hubs?

Africa Harvest **Project managment**


Pioneer Hi-Bred **Technology doner** and capability building support

Council for Scientific and Industrial Research, South Africa. **Technology recipient.**

National agricultural research institutes (KARI, ARC, INERA) . Field trial and expertise providers

Universities Pretoria, and California Berkeley. **Analytics.**

National instituions e.g. CORAF/ WECARD, AH. **Policies and stakeholder awareness/acceptance.**



EGONET AATF

Lines: represent shared projects


Other hubs

KARI (Kenyan Agricultural Research Institute and Agricultural Research Investments and Services (ARIS)). Activities incl. Insect resistant maize for Africa

BecA (Biosciences eastern and central Africa)) in Nairobi, Kenya. Activities of the BecA Hub include drought tolerant maize, understanding drought tolerance of cassava, striga control, infectious diseases of east african livestock, Tef cereal improvment

The crops perspective: some insights

(Agricultural PPPs mainly in 2000-2010)



Insight:

- •Do we have the right mix?
- •Can investments in orphan crops produce as outstanding a return as has been seen with broadacre crops?

 Food Policy 29
 (2004)15–44)
- •Are we investing enough?


ORice, wheat and maize are the most important food crops of the developing countries...centre of global agricultural development policy

Global Alliance for Improving Food Security and the Livelihoods of the Resourcepoor in the Developing World, 2011

The crops perspective: some insights

(Agricultural PPPs mainly in 2000-2010)

Crop focus of CGIAR compared to that of GCP in PPPs



GCP focus crops		
barley		
beans		
cassava		
chickpeas		
cowpeas		
groundnuts		
maize		
millet		
rice		
sorghum		
sweet potatoes		
wheat		

ORice, wheat and maize are the most important food crops of the developing countries...centre of global agricultural development policy


Global Alliance for Improving Food Security and the Livelihoods of the Resourcepoor in the Developing World, 2011

Insight:

•Do we have the right mix?

What crops are we focusing on?


(Agricultural PPPs mainly in 2000-2010)



Insight:


Agro Science multinationals and CGIAR have a similar balance
Foundations are closer to NARIs Hubs and farmers





What traits are we working on?: some insights

(Agricultural PPPs mainly in 2000-2010)



Insight:

- •Does this focus reflect global needs in AG?
- •Pest resistance/control and herbicide tolerance is the biggest single chunk, reflecting the major expertise of the multinationals
- •Taken together, stress tolerance, nutrient efficiency and biofortification however exceeds the pest control area! (..in keeping with current concerns?)

Historical perspective of PPPs in GM

•Papaya RSV

'Noughties' 2010-30 1990's Address **Donations** The times they are remaining don't work a-changing challenges Lack of involvement More participative approach Regulation of private sector E.g. Market access •WEMA E.g. Segregation •IRMA 1 •IMAS •Golden Rice 1 VIRCA •VR sweet potatoes •DT wheat and rice

> Addressing 'capacity building' But regulatory barriers remain

Agbiotech perspective: some insights

(Agricultural PPPs mainly in 2000-2010)

Will Agbiotech Applications Reach Marginalized Farmers? (Spielman, Cohen, Zambrano, 2006)

..although developing countries invest in agricultural biotechnology and genetically modified crop research, their policy and investment environments inhibit the contribution of such research to agricultural development and poverty reduction.

..valuable private-sector resources are not being brought to bear on the development challenge. For such research to benefit developing countries, greater effort is needed to enhance the international exchange of safety and efficacy information, remove the isolation of public research institutions, and overcome barriers to public-private research collaboration.

BASF and Embrapa's biotech soybeans on track for Brazilian market launch from 2011 onward 2009-01-30 First seeds expected to be available to Brazilian farmers from 2011 onward


SÃO SAULO and BRASÍLIA, Brazil, January 30, 2009 – BASF and Embrapa, Empresa Brasileira de Pesquisa Agropecuária, today announced that the organizations' jointly developed herbicide-tolerant soybean has been submitted for regulatory approval. Embrapa is Brazil's's public agricultural research. The package includes herbicide tolerant genes supplied by BASF, which Embrapa's scientists inserted into soybean. The cooperation dates back to 1997.

Insight:

- •View 1 suggests that the major barrier to PPP succeeding is the inefficient management of resources
- View 2 suggests that success is blocked only by regulatory (and hence social concerns) grounds
- •How do we decide which risk to focus on? Is the consideration whether an innovation is GM or not, an oversimplification?

Value Chain perspective: some insights

(Agricultural PPPs mainly in 2000-2010)



Insight:

•41% of the projects do not mention plans for how products will be developed. 59% do, 5% are actually about the full chain, but only 8 % have actually succeded to bring products to market •Do we mitigate sufficiently against the risks of not reaching the farmer?

The challenges for PPPs

- Public and private partners are challenged by fundamentally different incentives.
- Public and private partners do not adequately account for and minimize the direct and hidden costs of a collaborative research investment.
- Public and private partners are hindered by persistent negative perceptions of each other.
- Public and private partners are constrained by the lack of creative organizational mechanisms to reduce intersectoral competition for key assets and resources.
- Public and private partners are impeded by the limited availability of information on successful working models of partnership.

Spielmann & Grebmer, 2004



Conflict of interest issues in PPPs.

Since partnerships between public (by which we mean non profit) and private (by which we mean for profit) organizations will invariably raise issues of COI, the recognition and management of these COIs is critical to the existence of these partnerships.

Omobowale et al. 2010

Success factors: comparing AG (philanthrophy?) and HEALTH (business case?)

Agriculture PPP views

- Oclear agreed objective
- both parties contribute something other than money
- Oclear definition of who does what
- Osingle project plan with milestones
- Oclear governance mechanism (inclu. for conflict resolution) Braun and Ferroni, 2008

- Ocombine explicit knowledge exchanges with experiential learning
- Relevant partners, incentive compatibility, mutual objectives, clear roles and reponsibilities
- Risk managementand mitigation
- OAnalyse impact pathways which improve marginalized social groups
 Spielmann, Hartwich,
 Grebmer, 2004

Health PPP views

PPPs are set up to address specific R&D gaps for diseases of the poor.

- high quality knowledgeable management with strong commercial experience
- Oscientific committee and board representation must be on expertise rather than representativeness ...of region or politics
- O a number of indicators need to be developed to measure performance
- OPPPs must pursue an aggressive IP strategy designed to maximise the social value of product and process patents
- Ocombination of PPP investment and push/pull incentives (e.g. a Global Purchase Fund, Tax credits) are needed for success .WHO Macroeconomic Commission on Health, 2001

Success factors: some lessons from Health

The public policy challenge is to construct incentives to engage public and private researchers so that they invest aggressively in R&D to **develop products for the neglected diseases of the poor.** The discussions about what to do have put forward two alternative models for R&D.

- (i) The first model the commercial approach strives to make neglected diseases as attractive as other, nonneglected, diseases to private companies looking to make investment decisions. By improving their expected profitability, these policies would incentivise more R&D into these diseases.
- (ii) In the second model, public -private partnerships (PPPs) are set up to address disease specific R&D gaps. The issues around the likely effectiveness of these PPPs ...

The two models are not mutually exclusive. An important conclusion of this study is that public private partnerships' success depends on there being credible pull mechanisms in place that enhance the expected size of the market and thereby incentivise major pharmaceutical companies to participate.

WHO Macroeconomic Commission on Health, 2001

Insight:

- •Developing products for the neglected diseases of the poor is parallel to the challenge in AG to seek support for improving orphan crops
 •Are these models relevant to
- •Are these models relevant to AG PPP?

Key risks

- coordinating diverse interests/mandates
- exchanging proprietary knowledge assets
- no risk management to mitigate against worst case scenarios
- no planning to resolve conflicts as they rise
- no adequate legal, financial, communication strategies to manage external threats

Spielman, Hartwich & Grebmer, 2004

Conclusions

Key gaps

- ODo we have the right mix: feed the world and feed the poor?
- OProjects pay insufficient attention...
 - to getting the product to market; go-to-market strategy
 - to managing resources; project management
- ONo consistent platform to share knowledge, and little cross project collaboration
- OLimited risk management to mitigate against problem scenarios or planning for conflict resolution
- Insufficient legal, financial, communication strategies to address external challenges

syngenta foundation for sustainable agriculture

Acknowledgements: This document is based on an original report by Khoon M Chin (2011). No illustrations may be reproduced or transmitted in any form or by any means without the approval of the Syngenta Foundation for Sustainable Agriculture.